The Pharmaceutical Pricing and Reimbursement Industry, 2014-2024 - During Q1 2020, Pharmaceutical Companies Witnessed a Boost in Sales as Wholesalers Stockpiled Products due to Supply Chain Concerns
Dublin, July 22, 2020 (GLOBE NEWSWIRE) -- The "Pharmaceutical Pricing and Reimbursement: Global Markets" report has been added to ResearchAndMarkets.com's offering.
During the first quarter of 2020, most pharmaceutical companies, such as Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, and Novartis, witnessed a short-term boost in sales as wholesalers stockpiled products due to supply chain concerns. Some areas such as physician or hospital administered medications and travel vaccines saw a decline in sales, for obvious reasons.
Mergers and acquisitions (M&A) activity in the pharmaceutical sector keeps ticking along, with 2019 being one of the most active years in the last decade, many transactions involved the acquisition of cell and gene therapies and immune-oncology assets or to diversify risks through the adoption of digital technologies and artificial intelligence (AI).
To contain healthcare costs, governments across the globe have introduced healthcare reforms and initiated new legislation and pharmaceutical regulations that look more closely at the performance and cost-effectiveness of care. The pharmaceutical regulatory landscape is highly fragmented and divergent, and the following section summarizes the regulatory processes adopted by the latest top five European countries and the U.S. However, as regulatory oversight increases there is a growing need for regulatory harmonization.
Since the first reports of COVID-19 in Wuhan, China in December 2019, there have been 5,165,481 confirmed cases and over 336,430 confirmed deaths in 216 countries worldwide, as of May 24, 2020. Relatively few countries remain unscathed by the pandemic and scientists across the globe have worked together to advise local, regional and national healthcare organizations to contain the spread of the disease and develop prophylactic vaccinations and new therapies to treat the symptoms of the viral infection. Each country has adopted its own healthcare strategies and mobilized resources based on their individual circumstances, but only by working together will the world be able to combat this lethal disease.
More than $830 million in funding has been pledged to support R&D efforts in COVID-19, and health tech and pharmaceutical companies are working together in public-private collaborations, while numerous diagnostics, vaccines, and treatments are already under development and research.
The COVID-19 pandemic has already dramatically changed healthcare delivery, and the economic impact of COVID-19 pandemic on healthcare spending is unknown. It will depend on many factors including level and severity of infection, availability of diagnostics prophylactic treatments and vaccines, and whether the health system can manage supply constraints and defer non-essential healthcare services.
Report Scope
This new report on pricing and reimbursement in a global market provides a brief overview of the pharmaceutical markets, healthcare reforms, and regulations across the globe over the last decade and how this has impacted mergers and acquisitions and venture capitalist investment in the sector. It reviews pricing and reimbursement policies and processes in the U.S. and Europe and the ways in which pharmaceutical investment in generics, biosimilars, over the counter (OTC), small molecule and biological agents; and the shift toward more innovative medicines such as cell and gene therapies may change future treatment paradigms and future pricing and reimbursement policies.
The report includes:
An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures
Analyses of the global market trends, with data corresponding to market size for 2014-2019, and projections of compound annual growth rates (CAGRs) through 2024
Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry
Case studies of different price and reimbursement strategies for prescription drugs, orphan drugs, generics, over-the-counter products, and value-based pricing
Discussion on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall healthcare marketplace
Insight into the greater adoption of value-based pricing schemes, with emphasis on the innovative payment models, increased investment in cell and gene therapies, and long-term response to COVID-19
Key Topics Covered
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Chapter 2 Summary and Highlights
Chapter 3 Global Healthcare Expenditures, Legislation and Pricing Mechanisms
Global Healthcare Costs
Forecasts Pre-COVID
Forecasts Post-COVID
Acute Healthcare Response to COVID-19
Expansion of Low-Cost Digital Services
Funding for COVID-19 Research and Development
Drug Expenditures
North America
Europe
Japan
BRIC Economies
Impact of COVID-19 on Pharmaceutical Sales in Q1 2020
Mergers and Acquisitions (M&A)
M&A Activity Pre-2019
M&A Activity in 2019
M&A Activity in Q1 2020
Healthcare Reforms
France
Germany
Italy
Spain
United Kingdom
United States
Pharmaceutical Regulation
France
Germany
Italy
Spain
United Kingdom
United States
Acute Impact of COVID-19 on Healthcare
France
Germany
Italy
Spain
United Kingdom
United States
Chapter 4 Pricing Strategies
Introduction
Primary Reasons for the Rise in the Cost of Pharmaceuticals
Replacement of Older, Lower-Cost Drugs by Newer, Higher Priced Drugs
Increased Use of Drugs
New Drugs for Diseases for Which No Treatment Was Previously Available
Increases in the Prices of Existing Medicines
Pharmaceutical Pricing Strategies
External Price Referencing
Internal Referencing Pricing
Prescription Drug Pricing
United Kingdom
United States
Over-the-Counter (OTC) Drug Pricing
Europe
United Kingdom
United States
Generic Drug Pricing
United Kingdom
United States
Orphan Drug Pricing
Value-Based Pricing
Open Tender Invitations and Procurement
Framework Agreements
Chapter 5 Reimbursement Strategies
Pharmaceutical Reimbursement
Admission to Reimbursement
Reimbursement Procedure
Europe
United Kingdom
United States
Hospital Reimbursement
Europe
United Kingdom
United States
Patient Access Schemes
Financially Based Schemes
Outcome-Based Schemes
Early Access to Medicines Schemes
Europe
United Kingdom
United States
Formulary Lists
Europe
United Kingdom
United States
Health Technology Assessments (HTA)
Europe
United Kingdom
United States
The Value of Health Economics and Outcome Research (HEOR)
Top 10 HEOR Trends
Chapter 6 The Future
Greater Adoption of Value-Based Pricing Schemes
Increased Investment in Cell and Gene Therapies
Innovative Payment Models
Greater Clarity on Brexit
Political Wrangling Over Drug Prices
Long-term Response to COVID-19 Undefined
Companies Mentioned
Bristol-Myers Squibb
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Novartis
For more information about this report visit https://www.researchandmarkets.com/r/mp3yy3
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900